Abstract 2109P
Background
Vitamin deficiencies and supplement intake is discussed controversially in oncology. Therefore, we aimed to investigate vitamin D, A and E levels and their correlation with clinical characteristics and symptomatic burden in a large pan-cancer cohort.
Methods
25-hydroxy-vitamin D, vitamin A, and vitamin E levels were measured at treatment start in patients receiving palliative cancer treatment at the Medical University of Vienna (MUV) included in the “Biobanking Program for Personalized Immunotherapy” between May 2019 and March 2022. Measurements were performed using a chemiluminescence immunoassay (vitamin D) and high performance liquid chromatography (vitamin A, vitamin E) established at the Department of Laboratory Medicine (MUV). Cut off values defining the normal range were predefined as follows: vitamin D (75-250nmol/L), vitamin A (1.05-2.45μmol/L), vitamin E (12.0-42.0μmol/L). Symptom burden was assessed using the EORTC quality of life questionnaire QLQC-30 and its subscore assessing fatigue.
Results
Vitamin D, A, and E levels were measured in a total of 231 patients (92 females, 139 males, median age: 64 years [range: 23-89]). Median vitamin levels were as follows: vitamin D 66.9nmol/l (range: 10.4-186.0nmol/l), vitamin A 1.64μmol/l (range: 0.29-4.22μmol/l), and vitamin E 35.8μmol/l (range: 20.2-76.8μmol/l). Patients presented with vitamin D deficiencies in 138/231 (59.7%) and vitamin A deficiencies in 34/231 cases (14.7%). No vitamin E deficiencies were detected, however, 25/231 patients (24.2%) presented with vitamin E levels above normal. Vitamin A levels were increased in 26/231 patients (11.3%), while vitamin D levels above the upper limit of normal in 1/231 patient (0.4%). No correlations between vitamin levels and clinical characteristics at sample collection such as sex, age, tumor origin, symptom burden or fatigue were observed (p>0.05). Additionally, no correlation between vitamin levels and overall survival could be detected (p>0.05).
Conclusions
Even though vitamin deficiencies are common in patients with cancer, no influences of vitamin levels on symptom burden, fatigue or survival could be detected.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Financial support by the Austrian Federal Ministry for Digital and Economic Affairs, the National Foundation for Research, Technology and Development and the Christian Doppler Research Association.
Disclosure
A.M. Starzer: Financial Interests, Personal, Invited Speaker, Lecture honoraria: AstraZeneca; Financial Interests, Institutional, Research Grant, Industry partner of institutional Christian Doppler Laboratory: Roche; Non-Financial Interests, Member, National Oncology Society: OeGHO; Non-Financial Interests, Member, Oncology society of USA: ASCO; Other, Travel support for conference participation: MSD, Lilly. M. Preusser: Financial Interests, Personal, Advisory Board: Bayer, Bristol Myers Squibb, Novartis, Gerson Lehrman, CMC Contrast, GSK, Mundipharma, Roche, BMJ Journals, MedMedia, AstraZeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dohme, Tocagen, Adastra, Gan & Lee Pharmaceuticals; Financial Interests, Institutional, Research Grant, Clinical Trials and research: Boehringer-Ingelheim, Bristol Myers Squibb, Roche, Daiichi Sankyo, Merck Sharp & Dohme, Novocure, GSK, AbbVie; Financial Interests, Institutional, Coordinating PI: PharmaMar; Non-Financial Interests, Leadership Role, Brain Tumor Group Chair (current): EORTC; Non-Financial Interests, Leadership Role, EANO Past-President (current): EANO; Non-Financial Interests, Other, Member Multi-Site Guideline Advisory Group: ASCO. A.S. Berghoff: Financial Interests, Personal, Invited Speaker: Roche, Bristol Myers Squibb, Merck, AstraZeneca; Financial Interests, Personal, Advisory Board: Daiichi Sankyo; Financial Interests, Institutional, Research Grant: Daiichi Sankyo, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
2055P - Multidisciplinary Tumor-ICU Board: Enhancing care for critically Ill patients with solid tumors in the ICU
Presenter: Francisco Javier Ros Montana
Session: Poster session 06
2056P - Hospitalization, reconsultations and mortality in the field of oncological emergencies: Who is at higher risk?
Presenter: Eugenia María Martínez Madrid
Session: Poster session 06
2057P - Prevalence of frailty in long-term prostate cancer survivors after radical prostatectomy and its association with quality of life and emotional health
Presenter: Valentin Meissner
Session: Poster session 06
2058P - Reducing waste to improve sustainability and affordability of cancer treatment: Redispensing unused oral anticancer drugs
Presenter: Lisa-Marie Smale
Session: Poster session 06
2059P - The impact of a dental oncology clinic for patients (pts) prescribed bone-modifying agents (BMA) in a cancer centre
Presenter: Harriet Byrne
Session: Poster session 06
2060P - Prevalence and predictor of poor mental adjustment to cancer before lung cancer surgery
Presenter: Junhee Park
Session: Poster session 06
2061P - Network analysis of comprehensive concerns in patients with cancer: Differences between the sexes
Presenter: Kazumasa Yamamoto
Session: Poster session 06
2062P - The psychological distress (PsyD) evaluation in pancreatic cancer (PC) patients (pts): A mono-institutional analysis
Presenter: Maria Bensi
Session: Poster session 06
2063P - Lifestyle changes as cancer treatment: It is time to get specific with our patients
Presenter: Ana Isabel Martin Quesada
Session: Poster session 06
2064P - Hospitalisation of patients with cancer: Identifying points for improvement in patient care in a university hospital in Spain
Presenter: Silvia Roa
Session: Poster session 06